Gastroscopic and pharmacokinetic evaluation of a new pivmecillinam tablet
- PMID: 6284518
- DOI: 10.1007/BF00606427
Gastroscopic and pharmacokinetic evaluation of a new pivmecillinam tablet
Abstract
Three different pivmecillinam preparations, a conventional 200 mg tablet (P tablet) and two new formulations containing respectively pivmecillinam 200 mg and 400 mg plus Avicel (microcrystalline cellulose) as a disintegrator (PA tablet), were compared in vitro and in a gastroscopic study in 8 healthy volunteers. Disintegration of the PA tablet was significantly more rapid both in vitro and in the stomach. Following disintegration, the content of the PA tablet was spread over a larger area of the gastric mucosa (1088 mm2) than was observed with the P tablets (408 mm2). Three of the 8 volunteers taking the P tablet developed hyperaemia, interstitial bleeding or erosions of the mucosa of the stomach. No such reactions were seen with the PA tablets. Serum concentrations of mecillinam following ingestion of pivmecillinam tablets were determined in three groups of subjects; fasting volunteers, both supine and ambulant, and in ambulant subjects who took the preparation with a light meal. There was a tendency for the new PA tablets to produce a higher peak serum level as well as greater bioavailability of mecillinam. Administration of the PA tablets with a meal significantly increased the peak serum level and total bioavailability of the drug. On the basis of our observations we recommend adoption of the new PA tablet, because of its quick passage through the oesophagus and its more rapid and complete disintegration in the stomach.
Similar articles
-
Safety, pharmacokinetics, and food-effect of pivmecillinam after single- and multiple-dose in healthy Chinese subjects: a phase I study.Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7639-7647. doi: 10.1007/s00210-024-03118-3. Epub 2024 May 1. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38691150 Clinical Trial.
-
Pharmacokinetics of bacmecillinam and pivmecillinam in volunteers.Eur J Clin Pharmacol. 1982;23(3):249-52. doi: 10.1007/BF00547563. Eur J Clin Pharmacol. 1982. PMID: 6293834 Clinical Trial.
-
Urinary excretion of mecillinam by volunteers receiving film-coated tablets of pivmecillinam hydrochloride.Chemotherapy. 1979;25(1):1-4. doi: 10.1159/000237814. Chemotherapy. 1979. PMID: 217572 Clinical Trial.
-
Pharmacokinetics of pivmecillinam.Br J Clin Pharmacol. 1977 Jun;4(3):267-73. doi: 10.1111/j.1365-2125.1977.tb00711.x. Br J Clin Pharmacol. 1977. PMID: 197981 Free PMC article.
-
Pharmacokinetics of amdinocillin and pivamdinocillin in normal volunteers.Am J Med. 1983 Aug 29;75(2A):60-4. doi: 10.1016/0002-9343(83)90095-5. Am J Med. 1983. PMID: 6311007
Cited by
-
Feasibility of capsule endoscopy for direct imaging of drug delivery systems in the fasted upper-gastrointestinal tract.Pharm Res. 2014 Aug;31(8):2044-53. doi: 10.1007/s11095-014-1306-6. Epub 2014 Feb 19. Pharm Res. 2014. PMID: 24549826
-
Safety, pharmacokinetics, and food-effect of pivmecillinam after single- and multiple-dose in healthy Chinese subjects: a phase I study.Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7639-7647. doi: 10.1007/s00210-024-03118-3. Epub 2024 May 1. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38691150 Clinical Trial.
-
Influence of food on bioavailability of amdinocillin pivoxil.Antimicrob Agents Chemother. 1988 Apr;32(4):592-4. doi: 10.1128/AAC.32.4.592. Antimicrob Agents Chemother. 1988. PMID: 3377469 Free PMC article.
-
What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.Dig Dis Sci. 2002 Aug;47(8):1665-78. doi: 10.1023/a:1016495221567. Dig Dis Sci. 2002. PMID: 12184516 Review.
-
Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review.Clin Infect Dis. 2025 Feb 24;80(2):280-299. doi: 10.1093/cid/ciae621. Clin Infect Dis. 2025. PMID: 39835818 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources